Skip to main content
Livermore
Livermore
ZHEN

Aclaris Therapeutics, Inc.

ACRS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001557746

No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Aclaris Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of ACRS: Q3 2024 compared with Q4 2024
MeasureQ3 2024Of which not filed for Q4 2024Q4 2024Change
Holders81298+19
Shares50.9M19.0K87.5M+36.6M (+71.9%)
Value$58.5M$21.8K$217.0M+$158.5M (+270.9%)

2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (34)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to ACRS in Q4 2024
InstitutionSharesValue% of portfolio
Adage Capital Partners GP, L.L.C.9,627,304$23.9M0.04%
Vivo Capital, LLC8,888,888$22.0M2.47%
Ra Capital Management, L.P.4,666,667$11.6M0.15%
Janus Henderson Group PLC2,799,759$6.99M0.00%
Marshall Wace, LLP2,634,065$6.53M0.01%
Decheng Capital LLC2,266,667$5.62M1.21%
Logos Global Management LP2,222,222$5.51M0.64%
Monashee Investment Management LLC888,888$2.20M0.30%
Walleye Capital LLC718,897$1.78M0.02%
Peapod Lane Capital LLC404,452$1.00M0.99%
Exome Asset Management LLC389,333$965.5K0.73%
Ikarian Capital, LLC350,000$868.0K0.25%
683 Capital Management, LLC217,265$538.8K0.05%
Raymond James Financial Inc154,351$382.8K0.00%
Schonfeld Strategic Advisors LLC131,895$327.1K0.00%
Boothbay Fund Management, LLC112,484$279.0K0.01%
Prelude Capital Management, LLC106,351$263.8K0.02%
Cantor Fitzgerald, L. P.100,000$248.0K0.01%
Alps Advisors Inc57,760$143.2K0.00%
Omers Administration Corp54,400$134.9K0.00%
Man Group plc53,534$132.8K0.00%
XTX Topco Ltd44,685$110.8K0.01%
Charles Schwab Investment Management Inc33,079$82.0K0.00%
Velan Capital Investment Management LP27,000$67.0K0.06%
Jain Global LLC24,460$60.7K0.00%
Caption Management, LLC17,960$44.5K0.00%
Alpine Global Management, LLC15,340$38.0K0.01%
Commonwealth Equity Services, LLC14,694$36.0K0.00%
Graham Capital Management, L.P.14,172$35.1K0.00%
Invesco Ltd.11,215$27.8K0.00%
ExodusPoint Capital Management, LP10,637$26.0K0.00%
MAI Capital Management1,500$3.72K0.00%
R Squared Ltd610$1.51K0.00%
SBI Securities Co., Ltd.66$1640.00%

Sold out (15)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of ACRS in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Trium Capital LLP1,912,990$2.20M
Acuitas Investments, LLC578,139$664.9K
Frazier Life Sciences Management, L.P.264,377$304.0K
Gsa Capital Partners LLP255,032$293.0K
ADAR1 Capital Management, LLC90,000$103.5K
BBR Partners, LLC60,000$69.0K
Tudor Investment Corp Et Al33,183$38.2K
Shay Capital LLC27,000$31.1K
Algert Global LLC19,770$22.7K
China Universal Asset Management Co., Ltd.13,722$15.8K
Two Sigma Securities, LLC10,740$12.4K
Mirae Asset Global Investments Co., Ltd.2,580$3.02K
SRS Capital Advisors, Inc.1,632$1.88K
Daiwa Securities Group Inc.248$0
CWM, LLC1$0

Not filed for Q4 2024 yet (2)

Institutions that held Aclaris Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ACRS in Q3 2024 that haven't filed for Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
AJOVista, LLC17,455$20.1K
Halpern Financial, Inc.1,500$1.75K